Daxor Corp (DXR)

$10.14 +0.64 (6.79%)
Market Cap 56.92M
Revenue (ttm) 1.45M
Net Income (ttm) -7.19M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -495.86%
Debt to Equity Ratio 0.00
Volume 2,782
Avg Vol 8,142
Day's Range N/A - N/A
Shares Out 5.84M
Stochastic %K 18%
Beta 0.27
Analysts Strong Sell
Price Target $23.50

Company Profile

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation opera...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 865-425-0555
Fax: 865-425-0551
Address:
109 Meco Lane, Oak Ridge, United States
akts
akts Jun. 10 at 8:43 PM
$DXR Why is this a public company? No one owns, no one trades. No activity. No interest. One product. Engineering tweaks every couple years. No sales activities. Just take it private, and keep it off my screen.
1 · Reply
Yi_YandH
Yi_YandH May. 29 at 8:06 PM
$DXR $SLS $ICU
0 · Reply
akts
akts May. 12 at 1:45 AM
$DXR VOLUME???? A month's worth today....WHY?
1 · Reply
Noahskskaaj
Noahskskaaj Apr. 28 at 2:00 AM
$DXR
0 · Reply
Yi_YandH
Yi_YandH Apr. 28 at 1:37 AM
$DXR
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 24 at 12:25 AM
$DXR
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Apr. 10 at 8:00 PM
$DXR CEO purchased 1,000 shares at $9.07 for a total of $9,070. Feldschuh Michael Richard now owns 213,694 shares. https://ceo-buys.com
0 · Reply
Noahskskaaj
Noahskskaaj Apr. 10 at 7:09 PM
$DXR does anyone have any information on an excpected date for the of their transition to a more stock style reporting of earnings other than before or around q2 2026
1 · Reply
focafoca99
focafoca99 Apr. 8 at 8:00 PM
$DXR said a high-volume Ohio cardiology center launched a new blood-volume-analysis program using its platform.
0 · Reply
iAccess_Alpha
iAccess_Alpha Mar. 10 at 8:51 PM
$DXR replay now available from iAccess Alpha’s Virtual Best Ideas Spring Conference. Access the webcast replay here: https://www.webcaster5.com/Webcast/Page/3157/53749 #microcap #smallcap #investing
0 · Reply
Latest News on DXR
Daxor Proxy statement: Proxy filing

Jun 3, 2026, 8:00 AM EDT - 20 days ago

Daxor Proxy statement: Proxy filing

Daxor trading resumes

2026-06-02T18:06:59.000Z - 21 days ago

Daxor trading resumes

Daxor trading halted, volatility trading pause

2026-06-02T18:00:14.000Z - 21 days ago

Daxor trading halted, volatility trading pause

Daxor issued patent from USPTO for absolute blood volume monitoring

2026-06-02T13:08:30.000Z - 21 days ago

Daxor issued patent from USPTO for absolute blood volume monitoring

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

Jun 2, 2026, 8:00 AM EDT - 21 days ago

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis

Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center

Apr 8, 2026, 8:00 AM EDT - 2 months ago

Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center

Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026

Mar 26, 2026, 8:00 AM EDT - 3 months ago

Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026

Daxor to showcase next-gen portable BVA at ACC.26 session

2026-03-17T12:25:59.000Z - 3 months ago

Daxor to showcase next-gen portable BVA at ACC.26 session

Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions

Mar 17, 2026, 8:00 AM EDT - 3 months ago

Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions

Daxor Transcript: IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026

Mar 10, 2026, 2:00 PM EDT - 3 months ago

Daxor Transcript: IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026

Daxor to debut portable blood volume analyzer at SCCM Critical Care Congress

2026-03-10T12:37:53.000Z - 3 months ago

Daxor to debut portable blood volume analyzer at SCCM Critical Care Congress

Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress

Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026

Mar 9, 2026, 8:00 AM EDT - 3 months ago

Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026

Daxor Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Daxor Slides: Corporate presentation

Daxor Earnings release: Q4 2025

Mar 3, 2026, 4:00 PM EST - 3 months ago

Daxor Earnings release: Q4 2025

Daxor issues update in Letter to Shareholders

2026-03-03T13:51:14.000Z - 4 months ago

Daxor issues update in Letter to Shareholders

Daxor reports NAV per share of $9.07

2026-03-03T13:05:11.000Z - 4 months ago

Daxor reports NAV per share of $9.07

Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share

Mar 3, 2026, 8:00 AM EST - 4 months ago

Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share

Daxor continues strategic expansion, opens new BVA program in Tennessee

2026-02-24T13:10:30.000Z - 4 months ago

Daxor continues strategic expansion, opens new BVA program in Tennessee

Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee

Feb 24, 2026, 8:00 AM EST - 4 months ago

Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee

Daxor initiated with a Buy at Lake Street

2026-02-11T13:41:32.000Z - 4 months ago

Daxor initiated with a Buy at Lake Street

Daxor to transition to Securities Exchange Act of 1934 reporting company

2026-02-10T13:21:00.000Z - 4 months ago

Daxor to transition to Securities Exchange Act of 1934 reporting company

Daxor prices 765,958 shares at $11.75 in registered direct offering

2026-01-23T13:11:18.000Z - 5 months ago

Daxor prices 765,958 shares at $11.75 in registered direct offering

Daxor Corporation Announces $9 Million Registered Direct Offering

Jan 23, 2026, 8:00 AM EST - 5 months ago

Daxor Corporation Announces $9 Million Registered Direct Offering

Daxor announces expansion of its BVA platform into three new facilities

2025-11-25T13:05:48.000Z - 7 months ago

Daxor announces expansion of its BVA platform into three new facilities

Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer

Nov 25, 2025, 8:00 AM EST - 7 months ago

Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer

Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit

Oct 21, 2025, 8:00 AM EDT - 8 months ago

Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit

Daxor to exhibit at the MedAxiom CV Transforum Fall’25 Conference

2025-10-15T12:15:43.000Z - 8 months ago

Daxor to exhibit at the MedAxiom CV Transforum Fall’25 Conference

Daxor debuts FDA-cleared BVA analyzer at HFSA meeting

2025-09-30T12:25:54.000Z - 9 months ago

Daxor debuts FDA-cleared BVA analyzer at HFSA meeting

Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA

Sep 30, 2025, 8:00 AM EDT - 9 months ago

Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA

Daxor unveils next-gen BVA analyzer at HFSA annual meeting

2025-09-23T12:15:36.000Z - 9 months ago

Daxor unveils next-gen BVA analyzer at HFSA annual meeting

Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting

Sep 23, 2025, 8:00 AM EDT - 9 months ago

Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting

Daxor’s blood volume analysis validated for COVID, sepsis patients

2025-09-04T12:10:58.000Z - 10 months ago

Daxor’s blood volume analysis validated for COVID, sepsis patients

Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care

Sep 4, 2025, 8:00 AM EDT - 10 months ago

Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care

Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 10 months ago

Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Daxor reports increase in NAV to $7.15 per share

2025-09-02T12:25:39.000Z - 10 months ago

Daxor reports increase in NAV to $7.15 per share

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

Daxor Slides: Corporate Presentation

Aug 27, 2025, 7:00 AM EDT - 10 months ago

Daxor Slides: Corporate Presentation

Why Is Daxor Stock (DXR) Up 20% Today?

2025-08-07T16:33:00.000Z - 11 months ago

Why Is Daxor Stock (DXR) Up 20% Today?

Daxor receives FDA clearance for new BVA system

2025-08-07T12:01:42.000Z - 11 months ago

Daxor receives FDA clearance for new BVA system

Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System

Aug 7, 2025, 7:55 AM EDT - 11 months ago

Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System

Daxor's Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Daxor's Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions

Daxor Proxy statement: Proxy Filing

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Daxor Proxy statement: Proxy Filing

Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal

May 14, 2025, 8:00 AM EDT - 1 year ago

Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal

Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems

May 13, 2025, 8:00 AM EDT - 1 year ago

Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems

Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology

May 7, 2025, 8:00 AM EDT - 1 year ago

Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology

Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance

May 6, 2025, 8:00 AM EDT - 1 year ago

Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance

Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions

Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025

New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival

Apr 15, 2025, 8:00 AM EDT - 1 year ago

New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival

Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo

Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks

Daxor Earnings Call Transcript: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Daxor Earnings Call Transcript: Q4 2024

Daxor Shareholder letter: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Daxor Shareholder letter: Q4 2024

Daxor Annual report: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Daxor Annual report: Q4 2024

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

Mar 4, 2025, 4:55 PM EST - 1 year ago

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

Mar 4, 2025, 3:53 PM EST - 1 year ago

Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Mar 4, 2025, 9:00 AM EST - 1 year ago

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Mar 4, 2025, 8:00 AM EST - 1 year ago

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center

Feb 28, 2025, 8:00 AM EST - 1 year ago

Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center

Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals

Feb 27, 2025, 8:00 AM EST - 1 year ago

Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals

Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025

Feb 19, 2025, 8:00 AM EST - 1 year ago

Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025

TruLite Health Bolsters Health Equity Expertise with Expanded Leadership Team

Feb 18, 2025, 10:50 AM EST - 1 year ago

TruLite Health Bolsters Health Equity Expertise with Expanded Leadership Team

ARDT

Daxor to Exhibit at World's Largest Critical Care Conference

Feb 18, 2025, 8:00 AM EST - 1 year ago

Daxor to Exhibit at World's Largest Critical Care Conference

Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment

Feb 14, 2025, 8:00 AM EST - 1 year ago

Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment

New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care

Feb 13, 2025, 8:00 AM EST - 1 year ago

New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care

Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum

Dec 18, 2024, 8:00 AM EST - 1 year ago

Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum

DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24

Oct 9, 2024, 8:00 AM EDT - 1 year ago

DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24

Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device

Sep 27, 2024, 5:00 PM EDT - 1 year ago

Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024

Leading Central Florida Hospital Implements Daxor's BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care

Sep 4, 2024, 8:30 AM EDT - 1 year ago

Leading Central Florida Hospital Implements Daxor's BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care

Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter

Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 12:15 PM EDT - 1 year ago

Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network

Daxor Quarterly report: Q2 2024

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Daxor Quarterly report: Q2 2024

Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide

Aug 5, 2024, 8:00 AM EDT - 2 years ago

Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide

Daxor Proxy statement: Proxy Filing

Jun 21, 2024, 8:00 AM EDT - 2 years ago

Daxor Proxy statement: Proxy Filing

Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting

Jun 18, 2024, 8:00 AM EDT - 2 years ago

Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting

akts
akts Jun. 10 at 8:43 PM
$DXR Why is this a public company? No one owns, no one trades. No activity. No interest. One product. Engineering tweaks every couple years. No sales activities. Just take it private, and keep it off my screen.
1 · Reply
Yi_YandH
Yi_YandH May. 29 at 8:06 PM
$DXR $SLS $ICU
0 · Reply
akts
akts May. 12 at 1:45 AM
$DXR VOLUME???? A month's worth today....WHY?
1 · Reply
Noahskskaaj
Noahskskaaj Apr. 28 at 2:00 AM
$DXR
0 · Reply
Yi_YandH
Yi_YandH Apr. 28 at 1:37 AM
$DXR
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 24 at 12:25 AM
$DXR
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Apr. 10 at 8:00 PM
$DXR CEO purchased 1,000 shares at $9.07 for a total of $9,070. Feldschuh Michael Richard now owns 213,694 shares. https://ceo-buys.com
0 · Reply
Noahskskaaj
Noahskskaaj Apr. 10 at 7:09 PM
$DXR does anyone have any information on an excpected date for the of their transition to a more stock style reporting of earnings other than before or around q2 2026
1 · Reply
focafoca99
focafoca99 Apr. 8 at 8:00 PM
$DXR said a high-volume Ohio cardiology center launched a new blood-volume-analysis program using its platform.
0 · Reply
iAccess_Alpha
iAccess_Alpha Mar. 10 at 8:51 PM
$DXR replay now available from iAccess Alpha’s Virtual Best Ideas Spring Conference. Access the webcast replay here: https://www.webcaster5.com/Webcast/Page/3157/53749 #microcap #smallcap #investing
0 · Reply
iAccess_Alpha
iAccess_Alpha Mar. 10 at 12:45 PM
$DXR will be presenting today at iAccess Alpha’s Virtual Best Ideas Spring Conference. March 10, 2026 | 2:00 PM ET Watch live via Stocktwits or access the webcast here: https://www.webcaster5.com/Webcast/Page/3157/53749 #microcap #smallcap #investing
0 · Reply
iAccess_Alpha
iAccess_Alpha Mar. 9 at 1:15 PM
$DXR will be presenting tomorrow at iAccess Alpha’s Virtual Best Ideas Spring Conference. March 10, 2026 | 2:00 PM ET Access the webcast here: https://www.webcaster5.com/Webcast/Page/3157/53749 #microcap #smallcap #investing
0 · Reply
iAccess_Alpha
iAccess_Alpha Mar. 6 at 10:41 PM
$DXR will present next week at iAccess Alpha’s Virtual Best Ideas Spring Conference. March 10, 2026 | 2:00 PM ET Access the webcast here: https://www.webcaster5.com/Webcast/Page/3157/53749 #microcap #smallcap #investing
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 27 at 7:15 PM
$DXR Current Stock Price: $11.86
0 · Reply
DipFalcon
DipFalcon Feb. 20 at 5:04 PM
$DXR Daxor Corp operates blood volume diagnostic services. Commercial adoption remains limited. Execution risk persists.
0 · Reply
MarketLurker
MarketLurker Feb. 10 at 2:21 PM
$DXR is a Daxor or medical device company; niche blood volume diagnostic market.
0 · Reply
alphawolftrading
alphawolftrading Feb. 5 at 8:20 AM
$DXR https://youtu.be/HFfIquKl4Gg?si=2jeoipMrf0v4TZEc
1 · Reply
SuperGreenToday
SuperGreenToday Jan. 24 at 9:13 PM
$DXR
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 26 at 11:10 PM
$DXR
0 · Reply